Bupropion
- Zyban is the slow-release form of the antidepressant bupropion - it is the first antidepressant licensed for smoking cessation
- unlike nicotine replacement therapy, treatment is started two weeks before quitting smoking
- one hypothesis suggests that Zyban might work in smoking cessation by increasing levels of noradrenaline and dopamine in the brain. This therefore counteracts the reductions in these neurochemicals that results from nicotine withdrawal
The summary of product characteristics should be consulted before prescribing this drug.
Related pages
- Cautions and contraindications
- Pharmacology
- Dose and administration
- Drug interactions
- Side effects
- Efficacy
- NICE guidance - use of nicotine replacement therapy (NRT), cytisinicline, varenicline and bupropion for smoking cessation
- Stopping smoking (evidence-based guidance)
- Naltrexone / bupropion in obesity
- Bupropion (Zyban) - risk of serotonin syndrome with use with other serotonergic drugs
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.